The new study provided an unprecedented, high-resolution evolutionary map of E. coli (Escherichia coli), an important step in developing precision medicine for antibiotic-resistant infections.
Researchers at the Wellcome Sanger Institute, the University of Oslo and Norway Arctic University UIT have leveraged large, long read sequences to track the genetic flow of E. coli plasmids.
This innovative study could be a pioneer in the precision treatment of infectious diseases such as urinary tract infections (UTIs) by targeting specific bacterial properties rather than relying on a wide range of antibiotics.
Mapping of Bacterial Evolution
By analyzing 4,485 plasmid genomes from over 2,000 E. coli blood flow samples collected over 16 years in Norway, scientists have successfully followed the genetic evolution of E. coli strains from 300 years ago.
This unprecedented mapping revealed the mechanisms behind plasmid-driven gene exchange and identified important barriers affecting gene transfer in bacterial strains.
Importantly, this study found that certain plasmids allow E. coli to produce bacteriocin. This is a protein that can kill closely related bacteria.
This finding could lead to a new precision medicine strategy using naturally occurring bacterial competition to combat antibiotic-resistant infections.
Utilize bacterial competition for targeted treatments
Contrary to the concept that bacteria primarily fight human therapy, E. coli strains are constantly competing with each other for the survival of the human intestine.
Most E. coli strains are harmless, but entering the bloodstream can cause severe infection, especially in immunocompromised individuals.
By understanding how plasmids contribute to antibiotic resistance and bacterial toxicity, researchers suggest a paradigm shift in precision therapy strategies.
If less harmful E. coli strains can beat more dangerous counterparts, they could potentially be introduced as a natural way to reduce the risk of infection.
The role of plasmids in antibiotic resistance
Plasmids are essential for the evolution of bacteria that act as carriers of genes associated with pathogenicity, survival, and antibiotic resistance.
The ability to migrate between bacterial strains complicates therapeutic efforts as resistance can spread rapidly.
This study allowed us to accurately track these genetic exchanges and provided irreplaceable insights into how resistance properties emerge and persist.
An important finding is that multidrug resistance and bacteriocin production are rarely seen in the same bacterial strain.
Clinical tests confirmed that strains carrying highly effective bacterially encoded genes can successfully inhibit non-carriers, including E. coli strains, which are the most common in the UK.
In particular, these bacteriocin-producing strains effectively target multidrug-resistant E. coli, suggesting potential alternatives to traditional antibiotics.
Professor Pol Johnsen, co-author of Norwegian Arctic University UIT, added:
“Our evolutionary map allows us to begin exploring this at a level that is impossible to ever be, by finally filling the decades-long evolution gap in plasmid evolution and providing a way to link this to what was happening in the world at the time.
“We have created new resources to tackle antibacterial resistant E. coli.
The future of precision medicine
This evolutionary map represents important advances in precision medicine and provides resources for targeted bacterial treatment strategies.
By identifying plasmids associated with harmful E. coli strains, future studies may develop highly specific therapies that neutralize dangerous bacteria without disturbing the beneficial microbiota.
Furthermore, the ability to predict bacterial outbreak based on historical plasmid tracing could transform public health strategies and enable aggressive infection control measurements.
This research lays the foundation for a new era of medicine. This is what precise treatment will replace the use of blanket antibiotics, reduce the increase in drug-resistant infections, and revolutionize bacterial disease management.
Source link
